Overview

Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2017-09-12
Target enrollment:
Participant gender:
Summary
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Pearl Therapeutics, Inc.
Treatments:
Budesonide
Formoterol Fumarate